Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, and fatty acid
metabolism has been well studied. Short-chain fatty acids (SCFAs) have been less …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Heart failure is a worldwide health problem with important consequences for the overall
wellbeing of affected individuals as well as for the healthcare system. Over recent decades …

Fecal samples from participants aged 60–80 were collected and sequenced by a high-
throughput second-generation sequencer to explore the structural composition of gut …

Despite considerable advances in the field, heart failure (HF) still poses a significant disease
burden among affected individuals since it continues to cause high morbidity and mortality …

Heart failure is a risk factor for adverse events such as sudden cardiac arrest, liver and
kidney failure and death. The gut microbiota and its metabolites are directly linked to the …

Background: Recent data indicated the importance of gut-kidney axis in the pathogenesis of
Immunoglobulin A nephropathy (IgAN). Growing evidences suggested the alterations of …

Background Increasing evidence supports that gut microbiota plays an important role in the
development of cardiovascular diseases. The prevalence of sarcopenia is increasing in …

Aims Cardiac energy metabolism is perturbed in ischaemic heart failure and is characterized
by a shift from mitochondrial oxidative metabolism to glycolysis. Notably, the failing heart …

Heart failure (HF) represents a group of complex clinical syndromes with high morbidity and
mortality and has a significant global health burden. Inflammation and metabolic disorders …